Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C37H56N2O3 |
Molar mass | 576.866 g·mol−1 |
3D model (JSmol) | |
| |
|
Menabitan (INN: SP-204) is a synthetic drug which acts as a potent cannabinoid receptor agonist.[1][2] It is closely related to natural cannabinoids of the tetrahydrocannabinol (THC) group, differing mainly by its longer and branched side chain, and the replacement of the 9-position carbon with a nitrogen. It's a structural analog of nabitan and dimethylheptylpyran.[1] It was studied as an analgesic in the 1970s and was found to possess analgesic effects in both humans and animals but was never marketed.[1][3][4]
Due to its structural similarity to the Schedule I/III drug THC, it can be treated as a Schedule I drug within the United States legal system under the Federal Analogue Act.